228 related articles for article (PubMed ID: 30889466)
1. Nitric oxide-donor/PARP-inhibitor combination: A new approach for sensitization to ionizing radiation.
Wilson A; Menon V; Khan Z; Alam A; Litovchick L; Yakovlev V
Redox Biol; 2019 Jun; 24():101169. PubMed ID: 30889466
[TBL] [Abstract][Full Text] [Related]
2. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
Sizemore ST; Mohammad R; Sizemore GM; Nowsheen S; Yu H; Ostrowski MC; Chakravarti A; Xia F
Mol Cancer Res; 2018 Jul; 16(7):1092-1102. PubMed ID: 29592899
[TBL] [Abstract][Full Text] [Related]
3. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
[TBL] [Abstract][Full Text] [Related]
4. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
5. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
6. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
7. DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation.
Abbotts R; Topper MJ; Biondi C; Fontaine D; Goswami R; Stojanovic L; Choi EY; McLaughlin L; Kogan AA; Xia L; Lapidus R; Mahmood J; Baylin SB; Rassool FV
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22609-22618. PubMed ID: 31591209
[TBL] [Abstract][Full Text] [Related]
8. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
9. Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage.
Giovannini S; Weller MC; Repmann S; Moch H; Jiricny J
Nucleic Acids Res; 2019 Sep; 47(17):9132-9143. PubMed ID: 31329989
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
Talens F; Jalving M; Gietema JA; Van Vugt MA
Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
[TBL] [Abstract][Full Text] [Related]
11. Resurrection of PARP Inhibitors in Breast Cancer.
Lyons TG; Robson ME
J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
[TBL] [Abstract][Full Text] [Related]
12. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition.
Luo ML; Zheng F; Chen W; Liang ZM; Chandramouly G; Tan J; Willis NA; Chen CH; Taveira MO; Zhou XZ; Lu KP; Scully R; Wulf GM; Hu H
Cancer Res; 2020 Jul; 80(14):3033-3045. PubMed ID: 32193285
[TBL] [Abstract][Full Text] [Related]
14. The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition.
Chatterjee P; Choudhary GS; Alswillah T; Xiong X; Heston WD; Magi-Galluzzi C; Zhang J; Klein EA; Almasan A
Mol Cancer Ther; 2015 Aug; 14(8):1896-906. PubMed ID: 26026052
[TBL] [Abstract][Full Text] [Related]
15. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Application of PARP Inhibitors in Neuro-Oncology.
Ning J; Wakimoto H
Trends Cancer; 2020 Feb; 6(2):147-159. PubMed ID: 32061304
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitor resistance: the underlying mechanisms and clinical implications.
Li H; Liu ZY; Wu N; Chen YC; Cheng Q; Wang J
Mol Cancer; 2020 Jun; 19(1):107. PubMed ID: 32563252
[TBL] [Abstract][Full Text] [Related]
19. Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.
Amin O; Beauchamp MC; Nader PA; Laskov I; Iqbal S; Philip CA; Yasmeen A; Gotlieb WH
BMC Cancer; 2015 Oct; 15():817. PubMed ID: 26510816
[TBL] [Abstract][Full Text] [Related]
20. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]